Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:


Bonn Neuroscientists Participating in International Initiative for Study of Rare Diseases

Scientists from the German Center for Neurodegenerative Diseases (DZNE) are participating in an international research project on the causes of rare degenerative brain and muscle disorders.

Over the next five years, the DNZE Bonn site will receive 470,000 euros for the effort. The project, entitled "NEUROMICS: Integrated European Project on Omics Research of Rare Neuromuscular and Neurodegenerative Diseases," is being funded under the EU's Seventh Framework Programme for Research.

The partners in the effort hail from Europe, Australia, Canada and the United States.

"Such a concerted effort on this scale is unprecedented," explains Prof. Thomas Klockgether, Director of Clinical Research at the DZNE. Relevant work in Bonn will focus on patients and healthy people with increased risks of disease. "We expect the work to yield new findings on the causes of such diseases and to provide impetus for diagnosis and therapy," notes Klockgether.

NEUROMICS is focused on a range of brain and movement disorders that are classified as "rare." That classification notwithstanding, in Europe alone the group of those affected – with symptoms including paralysis, muscle tremors, memory loss and dementia – amounts to more than half a million people. To date, only a limited range of therapies is available for easing these rare "neurodegenerative" and "neuromuscular" disorders. And little research has been conducted into the causes of such disorders. "Fortunately, the various disorders overlap in many areas, and virtually the same methods are always used to study them," Klockgether explains. "It thus makes a great deal of sense to tackle these diseases in the context of a single project."

A disease is considered "rare" when it affects fewer than five out of every ten thousand people. It is estimated that there are 6,000 to 8,000 such diseases. NEUROMICS is focusing on a total of ten of them: diseases such as Chorea Huntington, which involves motor and mental disorders, and the group of muscular dystrophies, which lead to muscle atrophy. "Several factors led to this selection," Klockgether reveals. "On the one hand, the diseases needed to be representative, i.e. to have a certain prevalence. On the other hand, the studies involved are only possible on the basis of long experience and a certain type of infrastructure, which is only available for certain diseases." The potential for including existing groups of patients within the studies is of central importance. "A relevant group of people has to be available. It can't simply be built on an ad hoc basis," emphasizes Klockgether.
The emphasis in Bonn: movement disorders

In NEUROMICS, DZNE researchers will be contributing expertise especially in the area of "ataxia". Ataxia sufferers have reduced muscle control, and they are prone to balance loss, incoordination and speech disorders. Such impairments are triggered by brain and spinal damage that can result from many different types of diseases. Klockgether, who is also head of the University of Bonn's Center for Rare Diseases, and his team are currently treating several hundred such patients.

One aspect of NEUROMICS includes studying persons who, while showing no symptoms, have an increased risk of disease as a result of their genetic disposition. "Such an increased risk may be found in close relatives of patients," explains Klockgether. "We are thus hoping that relatives of our patients will agree to take part in the studies."

Diversity of methods

Neurological disorders develop over long periods of time. Therefore noticeable findings can be made years before a disease makes an obvious appearance, Klockgether explains. "We are thus planning to study healthy persons with an increased risk of disease as comprehensively as possible." To carry out those plans, the researchers in Bonn will use a variety of different procedures, including magnetic resonance imaging (MRI) – which provides detailed views of the brain's interior – and tests of motor and cognitive skills.

In addition, blood samples will be taken from the persons being studied in Bonn and then analyzed by project partners, in the framework of the international cooperation for the effort. Those studies will make use of state-of-the-art technologies for gene and protein analysis. Such technologies are collectively referred to as "omics technologies" – as is reflected in the project name, NEUROMICS.
The technologies are expected to help identify "biomarkers". Biomarkers are indicators - found in blood tests results, genomic analysis or MRI scans (for example) - that can identify a disease before the first symptoms appear. Needless to say, biomarkers play a highly significant role in early detection.

Klockgether and his colleagues also plan to study underlying causes: "A number of these rare diseases are known to be inheritable," he notes. "At the same time, we are not aware of all of the genes involved in such inheritance. The specific objectives of NEUROMICS include finding such genes and thereby improving our understanding of the molecular triggers behind these diseases. This work may produce new approaches for therapies."

For further information:
The German Center for Neurodegenerative Diseases (DZNE) studies the causes of diseases of the nervous system and develops strategies for relevant prevention, therapy and care. An institution within the Helmholtz Association of German Research Centres, it has sites in Berlin, Bonn, Dresden, Göttingen, Magdeburg, Munich, Rostock/Greifswald, Tübingen and Witten. The DZNE cooperates closely with universities, their clinics and other research facilities. Website:

Dr. Marcus Neitzert | idw
Further information:

More articles from Health and Medicine:

nachricht Scientists develop tiny tooth-mounted sensors that can track what you eat
22.03.2018 | Tufts University

nachricht NIH scientists describe potential antibody treatment for multidrug-resistant K. pneumoniae
14.03.2018 | NIH/National Institute of Allergy and Infectious Diseases

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Researchers Discover New Anti-Cancer Protein

An international team of researchers has discovered a new anti-cancer protein. The protein, called LHPP, prevents the uncontrolled proliferation of cancer cells in the liver. The researchers led by Prof. Michael N. Hall from the Biozentrum, University of Basel, report in “Nature” that LHPP can also serve as a biomarker for the diagnosis and prognosis of liver cancer.

The incidence of liver cancer, also known as hepatocellular carcinoma, is steadily increasing. In the last twenty years, the number of cases has almost doubled...

Im Focus: Researchers at Fraunhofer monitor re-entry of Chinese space station Tiangong-1

In just a few weeks from now, the Chinese space station Tiangong-1 will re-enter the Earth's atmosphere where it will to a large extent burn up. It is possible that some debris will reach the Earth's surface. Tiangong-1 is orbiting the Earth uncontrolled at a speed of approx. 29,000 km/h.Currently the prognosis relating to the time of impact currently lies within a window of several days. The scientists at Fraunhofer FHR have already been monitoring Tiangong-1 for a number of weeks with their TIRA system, one of the most powerful space observation radars in the world, with a view to supporting the German Space Situational Awareness Center and the ESA with their re-entry forecasts.

Following the loss of radio contact with Tiangong-1 in 2016 and due to the low orbital height, it is now inevitable that the Chinese space station will...

Im Focus: Alliance „OLED Licht Forum“ – Key partner for OLED lighting solutions

Fraunhofer Institute for Organic Electronics, Electron Beam and Plasma Technology FEP, provider of research and development services for OLED lighting solutions, announces the founding of the “OLED Licht Forum” and presents latest OLED design and lighting solutions during light+building, from March 18th – 23rd, 2018 in Frankfurt a.M./Germany, at booth no. F91 in Hall 4.0.

They are united in their passion for OLED (organic light emitting diodes) lighting with all of its unique facets and application possibilities. Thus experts in...

Im Focus: Mars' oceans formed early, possibly aided by massive volcanic eruptions

Oceans formed before Tharsis and evolved together, shaping climate history of Mars

A new scenario seeking to explain how Mars' putative oceans came and went over the last 4 billion years implies that the oceans formed several hundred million...

Im Focus: Tiny implants for cells are functional in vivo

For the first time, an interdisciplinary team from the University of Basel has succeeded in integrating artificial organelles into the cells of live zebrafish embryos. This innovative approach using artificial organelles as cellular implants offers new potential in treating a range of diseases, as the authors report in an article published in Nature Communications.

In the cells of higher organisms, organelles such as the nucleus or mitochondria perform a range of complex functions necessary for life. In the networks of...

All Focus news of the innovation-report >>>



Industry & Economy
Event News

Virtual reality conference comes to Reutlingen

19.03.2018 | Event News

Ultrafast Wireless and Chip Design at the DATE Conference in Dresden

16.03.2018 | Event News

International Tinnitus Conference of the Tinnitus Research Initiative in Regensburg

13.03.2018 | Event News

Latest News

Custom sequences for polymers using visible light

22.03.2018 | Materials Sciences

Scientists develop tiny tooth-mounted sensors that can track what you eat

22.03.2018 | Health and Medicine

Mat baits, hooks and destroys pollutants in water

22.03.2018 | Earth Sciences

Science & Research
Overview of more VideoLinks >>>